Growth Hormone News and Research RSS Feed - Growth Hormone News and Research

Growth hormone (GH) is a protein-based peptide hormone. It stimulates growth, cell reproduction and regeneration in humans and other animals. Growth hormone is a 191-amino acid, single-chain polypeptide that is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland.
Aeterna Zentaris plans to conduct Macrilen Phase 3 clinical study for AGHD

Aeterna Zentaris plans to conduct Macrilen Phase 3 clinical study for AGHD

Aeterna Zentaris Inc. today announced plans to conduct a new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency ("AGHD"), as well as a dedicated thorough QT study to evaluate the effect of Macrilen on myocardial repolarization. [More]
Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics, Inc. today announced longer-term data from a Phase II investigator-initiated study showing Waldenstrom's macroglobulinemia (WM) patients treated with IMBRUVICA (ibrutinib) experienced sustained disease control with an overall response rate (ORR) of 91% after a median of 19.1 months of treatment and a 2-year overall survival (OS) rate of 95%. [More]
Combined therapy boosts growth in short children with low IGF-1

Combined therapy boosts growth in short children with low IGF-1

Children with short stature benefit from receiving combined treatment with growth hormone and insulin-like growth factor-1, if they have low endogenous levels of the latter, a study shows. [More]
Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Novo Nordisk today announced the company will launch Novoeight (Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A. [More]
New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA) will be highlighted at the 2015 American Association for Cancer Research Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA. [More]
GH response poor in SGA children with good spontaneous catch-up growth

GH response poor in SGA children with good spontaneous catch-up growth

Spontaneous catch-up growth after birth in short children who were born small for gestational age is a negative predictor of their long-term response to growth hormone treatment, say researchers. [More]
Chiasma closes $70 million Series E financing round

Chiasma closes $70 million Series E financing round

Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closing of a $70 million Series E financing round. [More]
Study: Growth hormone can improve social impairment in patients with Phelan-McDermid syndrome

Study: Growth hormone can improve social impairment in patients with Phelan-McDermid syndrome

A growth hormone can significantly improve the social impairment associated with autism spectrum disorder (ASD) in patients with a related genetic syndrome, according to a pilot study conducted at the Icahn School of Medicine at Mount Sinai and published yesterday on Pub Med, a public database of biomedical topics maintained by the National Institutes of Health (study originally published in the December 12 issue of the journal Molecular Autism). [More]
Sleep loss can lead to diabetes, reveals new research

Sleep loss can lead to diabetes, reveals new research

Lack of sleep can elevate levels of free fatty acids in the blood, accompanied by temporary pre-diabetic conditions in healthy young men, according to new research published online February 19, 2015, in Diabetologia, the journal of the European Association for the Study of Diabetes. [More]
Adult survivors of childhood cancer at risk for pituitary hormone deficiencies

Adult survivors of childhood cancer at risk for pituitary hormone deficiencies

Decades after undergoing cranial irradiation for childhood cancer, St. Jude Children's Research Hospital investigators found that adult survivors of pediatric cancer remain at risk for pituitary hormone deficiencies that may diminish their health and quality of life. [More]
Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma Inc., a U.S. privately-held biopharma company, announced today that results from a multicenter Phase III study of the investigational new drug, octreotide capsules, were published online for early release on Feb. 9, ahead of print, by the Journal of Clinical Endocrinology & Metabolism. [More]
Scientists develop potential new therapy based on cow's immune molecules for hormone deficiencies

Scientists develop potential new therapy based on cow's immune molecules for hormone deficiencies

To help people with hormone deficiencies, scientists at The Scripps Research Institute have developed a potential new therapy based on an unlikely model: immune molecules from cows. [More]
Newly found peptide may reduce desire for food

Newly found peptide may reduce desire for food

Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders. [More]
Some genetic features associated with modern diseases are ancient

Some genetic features associated with modern diseases are ancient

Psoriasis, a chronic skin condition, can cause rashes that itch and sting. So why would a genetic susceptibility to this and other ailments persist for hundreds of thousands of years, afflicting our ancient ancestors, and us? [More]
Genetic support for insulin system role in growth hormone response

Genetic support for insulin system role in growth hormone response

Genetic determinants of insulin sensitivity are positively related to spontaneous growth and response to growth hormone treatment in children born small for gestational age, researchers have found. [More]
Hutchinson-Gilford Progeria Syndrome can be compared to normal aging, say scientists

Hutchinson-Gilford Progeria Syndrome can be compared to normal aging, say scientists

In a new research study, scientists from Vision Genomics, LLC, Insilico Medicine, Inc., and Howard University showed that Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) is comparable to normal aging with respect to cellular signaling pathways, and that HGPS truly recapitulates the normal aging process. [More]
Long years of diabetes research now ripe for reinterpretation

Long years of diabetes research now ripe for reinterpretation

Years of diabetes research carried out on mice whose DNA had been altered with a human growth hormone gene is now ripe for reinterpretation after a new study by researchers at KU Leuven confirms that the gene had an unintended effect on the mice's insulin production, a key variable in diabetes research. [More]
Ascendis Pharma initiates TransCon Treprostinil Phase 1 study in healthy volunteers

Ascendis Pharma initiates TransCon Treprostinil Phase 1 study in healthy volunteers

Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced that it has initiated a Phase 1 single ascending dose study of TransCon Treprostinil in healthy volunteers. [More]
FDA approves Novo Nordisk’s weight loss injection, Saxenda

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. [More]
Chromosome X microduplications implicated in infancy-onset gigantism

Chromosome X microduplications implicated in infancy-onset gigantism

Researchers report that heritable microduplications on chromosome Xq26.3 may underlie a “striking” form of gigantism with onset in late infancy, and reveal a candidate culprit gene. [More]
Advertisement
Advertisement